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Abstract 
Reduced expression in immortalized cells/Dickkopf-3 (REIC/Dkk-3) was identified as a gene 
whose expression is reduced in many human cancers. REIC/Dkk-3 expression is also 
down-regulated in malignant glioma and regulates cell growth through caspase-dependent 
apoptosis. cRGD (EMD121974), an antagonist of integrins, has demonstrated preclinical 
efficacy against malignant glioma. In this study, we investigated the anti-glioma effect of 
combination therapy using an adenovirus vector carrying REIC/Dkk-3 (Ad-REIC) and cRGD. 
QRT-PCR revealed the reduction of REIC/Dkk-3 mRNA levels in malignant glioma cell lines. 
The reduction of REIC/Dkk-3 protein expression in malignant glioma cell lines was also 
confirmed with western blot analysis. After treatment with Ad-REIC and cRGD, the 
proliferative rate of malignant glioma cells was significantly reduced in a time-dependent 
manner. In vivo, there was a statistically significant increase in the survival of mice treated with 
Ad-REIC and cRGD combination therapy compared to Ad-REIC monotherapy. We identified 
an apoptotic effect following monotherapy with Ad-REIC. Moreover, cRGD augmented the 
anti-glioma efficacy of Ad-REIC. These results may lead to a promising new approach for the 
treatment of malignant glioma. 
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Introduction 
Malignant gliomas remain challenging tumors to treat, and a variety of experimental 
therapies have failed to show effectiveness in clinical trials 
1
. The median survival of 
aggressively treated patients with glioblastoma is approximately 14.6 months 
2
. The resistance 
of gliomas to the conventional therapeutic regimen of surgery, radiotherapy, and chemotherapy 
has prompted many investigators to seek novel therapeutic approaches for this fatal disease 
3
. 
Reduced expression in immortalized cells/Dickkopf-3(REIC/Dkk-3) was identified as a 
gene whose expression is reduced in many human cancers. REIC/Dkk-3 plays a role as a 
suppressor of the growth of several human cancers 
4, 5
. REIC/Dkk-3 also regulates the growth 
and survival of glioma cells by caspase-dependent and -independent mechanisms via 
modification of the Wnt signaling pathway 
4
. The Wnt signaling pathway regulates cell survival, 
at least in part, through inhibiting the proteasomal proteolysis of β-catenin 6. β-Catenin protein 
levels are reduced in a time-dependent manner inversely with the increased expression of 
REIC/Dkk-3 
4
. 
Integrins are expressed in tumor cells and tumor endothelial cells 
7-9
, and they play 
important roles in angiogenesis and invasion in glioma 
10-12. αvβ3 and αvβ5 integrins regulate 
cell adhesion 
13, 14
, and antagonists of these integrins suppress tumor growth in certain 
preclinical models 
15
. Several preclinical studies have shown an enhanced antitumor effect of 
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cRGD, an antagonist of these integrins, when it is administered in combinatorial therapeutic 
regimens 
16-21
. Mikkelsen et al. demonstrated that cRGD dramatically amplified the efficacy of 
radiation therapy in an animal glioma model 
22
. Previously, we demonstrated the enhanced 
therapeutic efficacy of oncolytic viruses on experimental glioma in combination with cRGD 
23-25
.  
In the present study, we infected primary malignant glioma cells with the REIC/Dkk-3 
gene using an adenovirus vector (Ad-REIC). We found that, in malignant glioma, REIC/Dkk-3 
expression was down-regulated and that the gene regulates cell growth through 
caspase-dependent apoptosis and a reduction in β-catenin expression. We investigated the 
therapeutic effect of Ad-REIC in a malignant glioma xenograft model by intratumoral injection. 
Moreover, we showed the anti-glioma effect of combination therapy with Ad-REIC and the 
integrin antagonist cRGD. 
 
Results 
mRNA and protein expression of REIC/Dkk-3 in malignant glioma cell lines and normal 
human astrocytes 
REIC/Dkk-3 mRNA expression was determined in normal human astrocyte (NHA) cells and the 
malignant glioma cell lines U251, Gli36Δ5, U87ΔEGFR using quantitative real-time 
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reverse-transcription PCR (QRT-PCR). The expression levels of REIC/Dkk-3 mRNA are 
displayed as a ratio between the target gene and a reference gene (glyceraldehyde 3-phosphate 
dehydrogenase; GAPDH) to correct for variation in the amounts of RNA. The relative target 
gene expression level was normalized to the value from NHA cells (value = 1.0). REIC/Dkk-3 
mRNA levels were lower in the malignant glioma cell lines than in NHA cells (relative 
quantification in U87ΔEGFR, U251, and Gli36Δ5: 0.00017, 0.073, and 0.374, respectively) 
(Figure 1A). The expression of REIC/Dkk-3 in malignant glioma cells was determined using 
western blot analysis, and protein band density was calculated using ImageJ software. 
REIC/Dkk-3 protein was detected as two major bands of ~60 and ~68 kDa. REIC/Dkk-3 
expression was reduced in the malignant glioma cell lines compared with NHA cells, taking the 
REIC/Dkk-3 protein level in NHA cells as 1.0. The protein levels of REIC/Dkk-3 were as 
follows: U87ΔEGFR cells, 0.009; U251 cells, 0.106; Gli36Δ5 cells, 0.235; P < 0.01 (Figure 1B, 
C). 
 
Overexpression of REIC/Dkk-3 protein with Ad-REIC 
To examine the possible use of REIC/Dkk-3 as a tool for targeted gene-based therapy, we 
overexpressed REIC/Dkk-3 using Ad-REIC under the control of the CAG promoter 
5
. An 
adenoviral vector carrying the LacZ gene with a CAG promoter (Ad-LacZ) was used as the 
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control vector. These adenoviral vectors were generated using replication-defective 
adenoviruses of serotype 5. REIC/Dkk-3 protein levels in U87ΔEGFR glioma cells at 36 h after 
treatment with Ad-REIC at a multiplicity of infection (MOI) of 10 were increased 
(Supplementary figure 1) (P < 0.001). The expression levels of REIC/Dkk-3 protein in 
U87ΔEGFR glioma cells at 36 h after treatment with Ad-REIC (MOI 10) and cRGD (0.1 μM) 
were increased as well as in cells treated with Ad-REIC (MOI 10) alone. 
 
Expression of integrin αvβ3 and αvβ5 in cells treated with cRGD  
U87ΔEGFR cells were treated with the indicated concentration of cRGD for 24 h and stained by 
immunofluorescence to assess integrin αvβ3 and αvβ5 expression, which was analyzed by flow 
cytometry. The initial expression levels of integrin αvβ3 and αvβ5 were remarkably high, while 
their expression in the presence of cRGD was slightly decreased at 1.0 µM and 10 µM in a 
dose-dependent manner (Figure 2). 
 
Effect of cRGD on adenovirus infection and gene expression 
Viral titers were calculated with the use of an Adeno-X qPCR Titration Kit (Clontech 
Laboratories, Mountain View, CA, USA) . The viral titer of the infected cells with Ad-LacZ was 
decreased when cRGD was added at 3 h before treatment with Ad-LacZ (Figure 3A). Moreover, 
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the adenovirus-mediated gene expression of LacZ in U87ΔEGFR cells was visualized by 
staining with X-gal. The expression levels of LacZ were significantly decreased when cRGD 
was added at 3 h before treatment with Ad-LacZ (Figure 3Ba–e). 
 
Cytotoxic effect of Ad-REIC and combination treatment with cRGD 
On the basis of the results shown above, to avoid cRGD interfering with viral infection, we 
utilized the following protocol: initially, glioma cells were infected with adenovirus, the media 
containing adenovirus were aspirated at 3 h after infection, and the cells were then incubated in 
fresh media containing cRGD at different concentrations. The cytotoxic effect of Ad-REIC and 
cRGD on glioma cells was investigated in vitro. The glioma cell lines were incubated with 
cRGD (0.1 or 1.0 μM) and Ad-REIC or Ad-LacZ at an MOI of 10 for the indicated time. The 
proliferation rate of the malignant glioma cells was decreased by treatment with Ad-REIC or 
cRGD in a time-dependent manner (Figure 4A, B). The combination of Ad-REIC and cRGD 
decreased the proliferation rate of the cells more than monotherapy. Moreover, to assess the 
effect of this combination, the cells were infected Ad-REIC at an MOI of 0 or 10 and 
subsequently treated with cRGD at a concentration of 0 or 0.1 μM. At 72 h after treatment with 
Ad-REIC and cRGD, the combination index (CI) in U87ΔEGFR cells was 0.80 and the CI in 
Gli36Δ5 cells was 0.87. This result indicated that the combination of Ad-REIC and cRGD 
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induced synergistic cytotoxicity. 
 
Apoptotic effect of Ad-REIC and cRGD combination treatment 
To confirm the apoptosis of the floating glioma cells treated with Ad-REIC and cRGD, the cells 
were stained using an In Situ Cell Death Detection Kit. Originally, U87ΔEGFR cells in culture 
were composed of bipolar cells; however, they became spherical and agglutinated when 
Ad-REIC and cRGD were added to the culture medium. In addition, Gli36Δ5 cells fused 
together when Ad-REIC and cRGD were added (Figure 5). Some of these deformed cells 
detached from the plate; these cells were stained by the terminal deoxynucleotidyl 
transferase-mediated dUTP nick-end labeling (TUNEL) method at 36 h after treatment with 
Ad-REIC and cRGD. As shown in Figure 6, TUNEL-positive cells were observed in the glioma 
cell lines (U87ΔEGFR and Gli36Δ5), but not in the NHA cells. A significant increase of 
TUNEL-positive cells was observed in the cells treated with Ad-REIC and cRGD monotherapy 
compared with Ad-LacZ (P < 0.001). Moreover, there was a significant increase in 
TUNEL-positive cells following combination therapy compared to Ad-REIC monotherapy, 
cRGD monotherapy, and control cells (Gli36Δ5: 47.7%, 10.4%, 13.0%, and 1.0%, respectively; 
all P < 0.001. U87ΔEGFR: 49.1%, 6.4%, 5.6%, and 0.6%, respectively; all P < 0.001). 
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Caspase expression and β-catenin degradation by REIC/Dkk-3 in malignant glioma cells 
U87ΔEGFR glioma cells were treated with Ad-LacZ at an MOI of 10, Ad-LacZ and cRGD (0.1 
μM), Ad-REIC at an MOI of 10, and Ad-REIC and cRGD combined. At 36 h after infection 
with Ad-REIC and at 33 h after adding cRGD or medium, glioma cells were harvested and the 
activity of caspase-8 and -9 was evaluated. In U87ΔEGFR cells, cRGD, Ad-REIC, and 
combination treatment induced the activated form of caspase-8. The cleaved form of caspase-9 
expression was also increased in cells treated with Ad-REIC as well as in cells treated with 
Ad-REIC and cRGD combined (Figure 7). 
Additionally, the Wnt signaling pathway regulates cell survival, at least in part, 
through inhibiting the proteasomal proteolysis of β-catenin. Therefore, we assessed its role on 
the expression of β-catenin in malignant glioma cells. β-Catenin protein levels were increased in 
the nucleus in a dose-dependent manner in U87ΔEGFR cells treated with cRGD. Conversely, 
β-catenin protein levels were reduced by Ad-REIC. Moreover, these levels decreased following 
combination treatment with cRGD and Ad-REIC (Figure 8). 
 
Effect of cRGD treatment on the therapeutic efﬁcacy of Ad-REIC in a xenograft mouse 
model 
The antitumor effect of Ad-REIC, cRGD, and Ad-REIC and cRGD combined was tested in mice 
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bearing intracerebral glioma (U87ΔEGFR). Kaplan-Meier survival curves were used to assess 
the survival time of the U87ΔEGFR mouse glioma model treated with Ad-LacZ, Ad-REIC, or 
Ad-REIC and cRGD combined. When we injected 2.0 × 10
8
 plaque-forming units (pfu) of the 
adenovirus, the survival time of mice treated with Ad-REIC was significantly longer than that of 
those treated with Ad-LacZ (median survival = 32 and 24 days, respectively; P = 0.0072; Figure 
9A). In the next protocol, we reduced the amount of the adenovirus to 2.0 × 10
7
 pfu. The 
survival time of mice treated with Ad-REIC and cRGD combined was significantly longer than 
that of those treated with Ad-LacZ or Ad-REIC alone (median survival = 25, 19, and 19 days, 
respectively; P = 0.0002; Figure 9B). An increased number of apoptotic cells was observed 
using the TUNEL assay in tumors treated with Ad-REIC and cRGD combined compared with 
Ad-REIC and control tumors (59.3%, 13.8%, and 2.2%, respectively; P < 0.0001; Figure 10). 
 
Discussion 
Our study indicated that the expression levels of REIC/Dkk-3 mRNA and protein were 
down-regulated in malignant glioma cell lines. The expression levels of REIC/Dkk-3 protein 
in U87ΔEGFR glioma cells after treatment with Ad-REIC and cRGD were increased as well as 
in cells treated with Ad-REIC alone. In vitro, after treatment with Ad-REIC and cRGD, the 
proliferation rate of malignant glioma cells was significantly reduced in a time-dependent 
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manner. In malignant glioma cells, increased REIC/Dkk-3 expression led to a remarkable 
increase in the number of TUNEL-positive cells. TUNEL-positive cells were observed in 
malignant glioma cell lines, but not among NHA cells. In vivo, the survival rate of mice treated 
with Ad-REIC and cRGD combination therapy was significantly improved compared to single 
treatment. In addition, an increased number of apoptotic cells was revealed by the TUNEL assay 
in tumors treated with Ad-REIC and cRGD combined compared with Ad-REIC and control. 
 
Effect of Ad-REIC on glioma in vitro 
We found that the increased expression of REIC/Dkk-3 by using an adenovirus vector led to a 
remarkable increase in the number of TUNEL-positive cells. Mizobuchi et al. reported that the 
overexpression of REIC/Dkk-3 with a plasmid vector induced apoptosis in malignant glioma 
cells 
4
. The REIC/Dkk-3 gene regulates cell growth through caspase-dependent apoptosis, 
especially via caspase-9. Our data also showed that the activated form of caspase-9 in glioma 
cells treated with Ad-REIC was significantly higher than in those treated with control. 
Moreover, β-catenin expression was decreased with the increased expression of 
REIC/Dkk-3. The activation of the Wnt signaling pathway is thought to contribute to the 
development of some human cancers, and β-catenin is considered a key element of the Wnt 
signaling pathway. Wnt signaling inhibits the release of cytochrome C and the subsequent 
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activation of caspase-9 induced by apoptotic stimuli 
26
. 
 
Advantage of combination therapy with cRGD 
Our results suggested that cRGD augmented the anti-glioma efficacy of Ad-REIC. 
Some reports have indicated the efficacy of combination therapy with cRGD. It has been used in 
combination with temozolomide against murine melanoma cells 
27
, with radiotherapy against 
human prostate cancer cells and human glioma cells 
28
, and with an oncolytic virus against rat 
and human glioma cells 
23, 24
. Similar to these reports, we found that cRGD augmented the 
anti-glioma efficacy of Ad-REIC. 
Previously, we showed that cRGD inhibited integrin binding and activated caspase-8 
through an extrinsic pathway 
21
. This caspase-8 activation effect of cRGD would enhance the 
effect of other cytotoxic therapies. In addition, Ad-REIC regulated cell growth through 
caspase-dependent apoptosis, mainly via caspase-9. The combination of the intrinsic pathway 
with caspase-9 activation and the extrinsic pathway with caspase-8 activation, is more efficient 
for inducing apoptosis than a single pathway 
23, 24
.  
For the upstream pathway, β-catenin protein levels were increased in the nucleus in a 
dose-dependent manner in glioma cells treated with cRGD. cRGD treatment reportedly induces 
the dissociation of cadherin from β-catenin 29 and, upon Wnt stimulation, results in an increase 
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in the “free” (uncomplexed to cadherin) cytosolic levels of β-catenin. This leads to its 
subsequent accumulation within the nucleus 
30, 31
. This indicates that cRGD accelerated the 
Wnt/β-catenin signaling pathway. Conversely, monotherapy with Ad-REIC decreased β-catenin 
expression. The suppression of Wnt signaling via Ad-REIC induced β-catenin degradation 4, 
preventing its translocation to the nucleus. Moreover, combination treatment of cRGD with 
Ad-REIC reduced the intra-nuclear levels of β-catenin protein more than Ad-REIC alone. As a 
result, cRGD could sensitize glioma cells to Ad-REIC treatment by increasing Wnt/β-catenin 
signaling. 
 
Efficacy of Ad-REIC on glioma in vivo 
From our results, the mice that received a single treatment of Ad-REIC (2.0 × 10
8
 pfu) had 
significantly prolonged survival compared to the Ad-LacZ-treated mice. This amount of virus 
was chosen in reference to previous reports. For malignant mesothelioma, 4.0 ×10
8
 pfu of 
Ad-REIC were injected 
32
. For gastric cancer, the mice were injected intraperitoneally with 1.0 
× 10
9
 pfu of Ad-REIC in 4 mL phosphate-buffered saline (PBS) 
33
. For prostate cancer, 1.2 × 
10
8
 pfu of an adenovirus vector carrying mouse REIC/Dkk-3 cDNA were injected 
intratumorally 
34
. Interestingly, the survival rate of mice treated with Ad-REIC and cRGD 
combination therapy was significantly improved compared to single treatment with Ad-REIC. 
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We could decrease the amount of virus from 2.0 × 10
8
 pfu to 2.0 × 10
7
 pfu by combination 
treatment. 
As a limitation of this study, in the in vivo experiments, there are not only tumor cells, 
but also other cell types, such as endothelial cells, endogenous astrocytes, and glial cells, that 
could express αvβ3/αvβ5. The effect of cRGD may not exclusively be owing to its effects on the 
injected tumor cells. Further studies are needed to elucidate this mechanism. 
 
Future directions 
We are developing Ad-REIC for use in clinical trials. The first-in-human, phase I/IIa clinical 
study of in situ Ad-REIC gene therapy for prostate cancer is being conducted at Okayama 
University Hospital. If the safety and efficacy of this therapy is proven, this might help us to 
perform a clinical trial for glioblastoma treatment with Ad-REIC. Certainly, as for cRGD, in the 
CENTRIC study (phase III), which compares the efficacy and tolerability of cRGD in patients 
with newly diagnosed glioblastoma and a methylated O6-methylguanine-DNA 
methyltransferase (MGMT) gene promoter status, cRGD failed to prolong progression-free 
survival or overall survival in patients with newly diagnosed glioblastoma and a methylated 
MGMT gene promoter. However, this point warrants a more detailed analysis with variation of 
the dosage of cRGD and Ad-REIC. Furthermore, we should also evaluate combination therapy 
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of Ad-REIC with other drugs such as temozolomide or bevacizumab. 
In conclusion, the overexpression of REIC/Dkk-3 induced apoptotic cell death in 
malignant glioma cell lines. Moreover, we revealed that cRGD augments the anti-glioma 
efficacy of Ad-REIC. 
 
Materials and methods 
Cell lines and reagents 
The glioma cell lines U87ΔEGFR, U251, and Gli36Δ5 were seeded on tissue culture dishes (BD 
Falcon, Franklin Lakes, NJ, USA) and cultured in Dulbecco’s modified Eagle’s medium 
supplemented with 10% fetal bovine serum, 100 U penicillin, and 0.1 mg/mL streptomycin. 
NHA cells were purchased from Takara Bio, Inc. (Shiga, Japan). 
cRGD was generously provided by Merck KGaA (Darmstadt, Germany) and the 
Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health. 
 
Adenovirus vector carrying REIC/Dkk-3 
For Ad-REIC under the control of the CAG promoter (CMV early enhancer/chicken β-actin 
promoter), the full-length human REIC/Dkk-3 gene was inserted into the cosmid vector 
pAxCAwt and then transferred into an adenoviral vector using the COS-TPC method (Takara 
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Bio, Inc., Shiga, Japan) 
5
. An adenoviral vector carrying the LacZ gene with a CAG promoter 
(Ad-LacZ) was used as the control vector. These adenoviral vectors were generated using 
replication-defective adenoviruses of serotype 5. 
 
QRT-PCR 
Total RNA was isolated from cultured glioma and NHA cells using an RNeasy® Mini Kit 
(QIAGEN, Hilden, Germany), and was reverse transcribed with oligo-dT primers using the 
SuperScript III First-Strand Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA, USA) 
according to the manufacturer’s instructions. Primers specific for each gene were designed 
using Primer 3 Plus Software 
(http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi) and synthesized by 
Invitrogen. The resulting cDNA was amplified by PCR using gene-specific primers and the 
StepOnePlus Real Time PCR System (Applied Biosystems, Foster City, CA, USA) and a 
QuantiTect
TM
 SYBR® Green PCR Kit (QIAGEN, Hilden, Germany). A log-linear relationship 
between the amplification curve and quantity of cDNA in the range of 1–1000 copies was 
observed. The cycle number at the threshold was used as the threshold cycle (Ct). mRNA 
expression levels were determined from 2-ΔΔCt using StepOne Software (version 2.2; Applied 
Biosystems, Foster City, CA, USA). The amount of cDNA in each sample was normalized to 
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the crossing point of the housekeeping gene GAPDH. The following thermal cycling parameters 
were used: denaturation at 95°C for 10 min followed by 45 cycles at 94°C for 15 s, 50°C for 30 
s, and 72°C for 30 s. The relative mRNA upregulation of each gene was calculated using their 
respective crossing points with the following formula, as described previously 
24
: REIC/DKK-3 
(forward) 5′-GTAAGTTCCCCTCTGGCTTG-3′, REIC/Dkk-3 (reverse) 
5′-AAGCACCAGACTGTGAAGCCT-3′, GAPDH (forward) 
5′-GGGTGTGAACCATGAGAAGTATGA-3′, GAPDH (reverse) 
5′-TGCTAAGCAGTTGGTGGTGC-3′. 
 
Viral titration assay 
PCR was performed employing an Adeno-X qPCR Titration Kit (Clontech Laboratories, 
Mountain View, CA, USA) and using a StepOnePlus Real-time PCR machine (Applied 
Biosystems, Foster City, CA, USA). The forward and reverse primers were provided in the kit. 
The PCR cycling conditions were 95°C for 30 s, followed by 95°C for 3 s and 60°C for 25 s for 
40 cycles, and then 95°C for 15 s, 60°C for 1 min, and 95°C for 15 s. The DNA copy number 
was determined from a standard curve generated by plotting the Ct values of the diluted 
Adeno-X DNA Control Template against their respective copy numbers, according to the 
manufacturer’s instructions. 
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LacZ staining 
Ad-LacZ-infected cells were detected using 5-Bromo-4-chloro-3-indolyl-β-D-galactopyranoside 
(X-gal) staining (Wako, Osaka, Japan). Suspended cells were attached to slides via Cytospin 
(Shandon Cytospin® Centrifuge; Thermo Scientific, Waltham, MA, USA). The cell were fixed 
in 2% formaldehyde and 0.2% glutaraldehyde at room temperature for 15 min, and then 
incubated overnight at 37°C in an X-gal solution. The cells were counted under a light 
microscope. 
 
Flow cytometry 
To measure the expression levels of integrin, U87ΔEGFR and Gli36Δ5 cells were exposed to a 
fluorescein isothiocyanate(FITC) -conjugated mouse anti-human integrin αvβ3 antibody 
(eBioscience, San Diego, CA, USA) and a phycoerythrin(PE)-conjugated mouse anti-human 
integrin αvβ5 antibody (R&D Systems, Minneapolis, MN, USA). Mouse IgG1 K isotype control 
FITC (eBioscience) and mouse IgG1 isotype control PE (R&D Systems) were used as controls. 
The samples were run on a flow cytometer (FACScan; Becton Dickinson, Franklin Lakes, NJ, 
USA) and analyzed using CellQuest software. 
 
Cytotoxicity assay 
The cells were cultured in a flat-bottomed 6-well dish at a concentration of 4.0 × 10
5
 cells per 
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well. The cells were infected with Ad-REIC or Ad-LacZ at an MOI of 10. The media containing 
adenovirus were aspirated at 3 h after infection, and the cells were then incubated in fresh media 
containing cRGD at a concentration of 0.1 μM for U87ΔEGFR and 1 μM for Gli36Δ5. At 48, 72, 
and 96 h later, the viability of the cells was examined. To determine the number of the cells 
attached to the bottom of each culture well, we used a Z2™ COULTER COUNTER® 
(Beckman Coulter, Brea, CA, USA) and counted the cells in 3 different wells. 
 To assess the combination effect of Ad-REIC and cRGD, the cells were infected 
Ad-REIC at an MOI of 0 or 10, the media containing adenovirus were aspirated at 3 h after 
infection, and subsequently treated with cRGD at a concentration of 0 or 0.1 μM. The 
combination index (CI) of Ad-REIC with cRGD was calculated as (observed fraction value of 
combination group) / (expected fraction value of combination group), in which the expected 
fraction value of combination group were estimated as (observed mean value of Ad-REIC) / 
(mean control value) × (observed mean value of cRGD) / (mean control value). CI < 1, = 1, and 
> 1 represent synergistic, additive, and antagonistic effects, respectively
35
. 
 
Western blot analysis 
The cells were cultured in a 100-mm dish (BD Falcon, Franklin Lakes, NJ, USA). Cell culture 
media were aspirated, the dishes were washed in PBS twice, and the cells were lysed in 1% SDS. 
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The lysates were sonicated for analysis of whole cell proteins. Nuclear proteins were isolated 
using an NE-PER Nuclear and Cytoplasmic Extraction Kit (Thermo Scientific, Waltham, MA, 
USA), according to the manufacturer’s instructions. Extracted protein samples were separated 
by gel electrophoresis and transferred onto PVDF membranes. After blocking in 5% skim milk, 
the membranes were incubated overnight with primary antibodies at 4°C. The membranes were 
washed with Tris-buffered saline-Tween 20 (TBST), incubated with secondary antibodies at 
room temperature for 1 h, and rinsed with TBST. Signals were visualized using the ECL Prime 
Western Blotting Detection System (GE Healthcare Life Sciences, Buckinghamshire, UK). The 
primary antibodies mouse anti-human REIC/DKK-3 (provided by the Department of Urology, 
Okayama University, Okayama, Japan), β-catenin, caspase-8 and -9, and TATA-binding protein 
(TBP) (Cell Signaling Technology, Danvers, MA, USA) were diluted 1:1000 in TBST. The 
β-actin antibody (Sigma, St. Louis, MO, USA) was diluted 1:5000 in TBST. The secondary 
antibody was horseradish peroxidase-conjugated anti-mouse or anti-rabbit IgG (Cell Signaling 
Technology, Danvers, MA, USA), diluted 1:6000 (REIC/Dkk-3, β-actin) or 1:2000 (β-catenin, 
caspase-8 and -9, and TBP) in TBST. 
 
Apoptosis assay 
Apoptotic tumor cells were detected using an In Situ Cell Death Detection Kit (Roche, 
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Mannheim, Germany). Suspended cells were attached to slides via Cytospin (Shandon 
Cytospin® Centrifuge; Thermo Scientific, Waltham, MA, USA). The cells were fixed in 4% 
paraformaldehyde at room temperature for 60 min, incubated in 3% hydrogen peroxide in 
methanol for 10 min at room temperature to block endogenous peroxidase activity, and then 
permeabilized for 2 min on ice with a permeabilization buffer. The cells were incubated at 37°C 
for 60 min in a TUNEL reaction mixture. Apoptotic cells were counted under a fluorescent 
microscope. For one experiment, the apoptotic cells were counted in 7 different fields, and the 
average percentage of apoptotic cells was calculated. 
 
In vivo experiments 
All experimental animals were housed and handled in accordance with the guidelines of the 
Okayama University Animal Research Committee. Before implantation, 85–90% confluent 
U87ΔEGFR cells were trypsinized and centrifuged at 100 × g for 5 min; the resulting pellet was 
resuspended in PBS, and the cell concentration was adjusted to 1.0 × 10
5 cells/μL. U87ΔEGFR 
cells (2 µL) were injected into 6-week-old BALB/c female nude mice (CLEA Japan, Inc., Tokyo, 
Japan). The mice were anesthetized and placed in stereotactic frames (Narishige, Tokyo, Japan) 
with their skulls exposed. Tumor cells were injected with a Hamilton syringe (Hamilton, Reno, 
NV, USA) into the right frontal lobe (3 mm lateral to the midline, 1 mm posterior to the coronal 
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suture, 3 mm depth from the dura) and the syringe was withdrawn slowly after 5 min to prevent 
reflux. The skulls were then cleaned, and the incision was sutured. Seven days following tumor 
inoculation, all mice bearing brain tumors were reanesthetized and subsequently injected with 
Ad-REIC and Ad-LacZ stereotactically at the tumor inoculation site using the same coordinates. 
cRGD and solvent were administered 3 times per week intraperitoneally at 200 µg/100 µL 
saline starting on Day 9 after tumor cell implantation. 
 
TUNEL staining in vivo 
An In Situ Cell Death Detection Kit, POD (Roche, Mannheim, Germany) was used for the 
TUNEL assay. The sections were deparaffinized and rehydrated. They were incubated in 0.3% 
hydrogen peroxide in methanol for 30 min at room temperature to block endogenous peroxidase 
activity. The sections were digested for 15 min using 20 μg/mL proteinase K, recombinant, PCR 
grade (Roche, Mannheim, Germany) in 10 mM Tris-HCl, pH 7.5. They were incubated with the 
TUNEL reaction mixture in a humidified chamber for 60 min at 37°C. They were then 
incubated with Converter-POD in a humidified chamber for 30 min at 37°C. The sections were 
lightly counter-stained with Mayer’s hematoxylin and analyzed under a light microscope. 
 
Statistical analysis 
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Data from the protein levels of REIC/Dkk-3, viral titration assay, and LacZ staining were 
analyzed using one-way analysis of variance (ANOVA) followed by Tukey’s post hoc test, and 
the percentage of TUNEL-positive cells in vitro and in vivo was analyzed using one-way 
ANOVA followed by the Games-Howell post hoc test. Kaplan-Meier curves were compared 
using the log-rank test. Statistical analysis was performed using SPSS statistical software 
(version 20; SPSS, Inc., Chicago, IL, USA). P-values < 0.05 were considered statistically 
signiﬁcant. 
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Figure legends  
Figure 1 
REIC/Dkk-3 mRNA levels in NHA cells and glioblastoma cell lines (A) were determined by 
QRT-PCR and expressed as molar ratios to those of GAPDH. QRT-PCR revealed a reduction in 
REIC/Dkk-3 mRNA levels in malignant glioma cell lines (relative quantification: U87ΔEGFR, 
0.00017; U251, 0.073; Gli36Δ5, 0.374; NHA, 1). (B, C) Western blot analysis revealed a 
reduction of REIC/Dkk-3 protein levels in malignant glioma cell lines compared to NHA cells 
(U87ΔEGFR, 0.009; U251, 0.106; Gli36Δ5, 0.235; NHA, 1). Protein band density was 
calculated using ImageJ software. Mean ± SD. * P < 0.01. 
 
Figure 2 
Expression levels of integrin αvβ3 and αvβ5. U87ΔEGFR cells were exposed to the indicated 
concentration (0, 1.0, or 10 μM) of cRGD for 24 h, stained by immunofluorescence for integrin 
αvβ3 (A) and αvβ5 (B) expression, and analyzed by flow cytometry. The initial expression 
levels of integrin αvβ3 (a) and αvβ5 (d) were remarkably high. cRGD at any concentration had 
little impact on both integrin αvβ3 (b, c) and αvβ5 (e, f) expression. Dotted lines: mouse IgG1 
isotype controls. 
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Figure 3 
Viral titer and LacZ expression under treatment with cRGD. (A) cRGD (0.1 or 1 μM) was added 
at 3 h before or at the same time as treatment with Ad-LacZ (MOI 10). After 3 h, viral titers 
were calculated using an Adeno-X qPCR Titration Kit (Clontech Laboratories, Mountain View, 
CA, USA). The viral titer of the infected cells with Ad-LacZ was decreased when cRGD was 
added at 3 h before treatment with Ad-LacZ. (B) The cells were incubated with media 
containing cRGD at a concentration of 0 or 0.1 μM for U87ΔEGFR. At 3 h before or 0 and 3 h 
later, the cells were infected with Ad-LacZ. The infection efficiency of Ad-LacZ to U87ΔEGFR 
cells was visualized by staining with X-gal. Each panel shows each time course: (a) adding 
cRGD at 3 h before viral infection, (b) at 0 h, (c) at 3 h after viral infection, (d) untreated with 
virus, and (e) Ad-LacZ alone. (C) Infection efficiency was significantly decreased when cRGD 
was added at 3 h before infection with Ad-LacZ. Bar = 200 μm. (A) Mean ± SD. * P = 0.001. 
**P = 0.002. (C) Mean ± SD. *P < 0.0001.  
 
Figure 4 
Cytotoxicity after treatment with Ad-REIC and cRGD. The cells were infected with Ad-REIC 
or Ad-LacZ at an MOI of 10. The media containing adenovirus were aspirated at 3 h after 
infection, and the cells were incubated in fresh media containing cRGD at a concentration of 0.1 
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μM for U87ΔEGFR and 1 μM for Gli36Δ5. At 48, 72, and 96 h later, the viability of the cells 
was examined. After treatment with Ad-REIC and cRGD, the proliferation rate of malignant 
glioma cells (A: U87ΔEGFR glioma cells, B: Gli36Δ5 glioma cells) was reduced compared to 
the other treatment groups in a time-dependent manner.  
 
Figure 5 
Most of the U87ΔEGFR cells treated with Ad-LacZ were composed of bipolar cells. However, 
they became spherical and agglutinated when they were treated with the combination of 
Ad-REIC (MOI = 10) and cRGD (0.1 μM) (top row, a-d). In addition, Gli36Δ5 cells fused 
together when they were treated with the combination of Ad-REIC (MOI = 10) and cRGD (1 
μM) (bottom row, e-h). Bar = 100 μm.  
 
Figure 6 
The combination of Ad-REIC and cRGD increased the number of TUNEL-positive cells. The 
cells were infected with Ad-REIC or Ad-LacZ at an MOI of 10. The media containing 
adenovirus were aspirated at 3 h after infection, and the cells were incubated in fresh media 
containing cRGD at a concentration of 0.1 μM for U87ΔEGFR and 1 μM for Gli36Δ5. After 36 
h, the cells were stained by the TUNEL method. Many TUNEL-positive cells were observed in 
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the glioma cell lines (A, B; Gli36Δ5 and C, D; U87ΔEGFR), but not in the NHA cells (E, F). A 
significant increase of TUNEL-positive cells was observed in the cells treated with Ad-REIC 
and cRGD monotherapy compared with Ad-LacZ. Moreover, there was a significant increase in 
TUNEL-positive cells treated with combination therapy compared to Ad-REIC single treatment, 
cRGD alone, and control cells (*P < 0.001). TUNEL-positive cells, green; DAPI 
(4′,6-diamidino-2-phenylindole; cell nuclei), blue. Bar = 100 μm. Mean ± SD. 
 
Figure 7 
Caspase-8 and -9 expression in U87ΔEGFR glioma cells after treatment with Ad-REIC and 
cRGD. U87ΔEGFR cells were infected with Ad-REIC or Ad-LacZ at an MOI of 10. At 3 h after 
infection, the cells were incubated in media containing cRGD at a concentration of 0.1 μM. 
Immunoblot analysis showed that cleaved caspase-8 was processed in the U87ΔEGFR cell line 
following treatment with cRGD and Ad-REIC. Cleaved caspase-9 was increased following 
treatment with Ad-REIC and combination treatment with cRGD. 
 
Figure 8 
Expression of β-catenin in the nucleus in U87ΔEGFR glioma cells after treatment with 
Ad-REIC and cRGD. (A) U87ΔEGFR cells were incubated with media containing cRGD at 
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different concentrations. β-Catenin expression was increased when U87ΔEGFR cells were 
treated with cRGD at a concentration of 0.01, 0.1 μM or more. (B) U87ΔEGFR cells were 
infected with Ad-REIC or Ad-LacZ at an MOI of 10. At 3 h after infection, the cells were 
incubated in media containing cRGD at a concentration of 0.1 μM. β-Catenin expression was 
decreased with the increased expression of REIC/Dkk-3. In addition, there was a significant 
decrease in the expression of β-catenin in cells treated with combination therapy compared with 
Ad-REIC monotherapy. 
 
Figure 9 
Kaplan-Meier survival curves of the U87ΔEGFR mouse glioma models treated with Ad-REIC 
or the combination of Ad-REIC and cRGD. (A) Seven days after tumor implantation, we treated 
the mice with Ad-REIC or Ad-LacZ (2.0 × 10
8
 pfu) by direct intratumoral injection. The 
survival time of mice treated with Ad-REIC was significantly longer than those treated with 
Ad-LacZ (median survival = 32 and 24 days, respectively; P = 0.0072). (B) In the next protocol, 
we reduced the amount of adenovirus to 2.0 × 10
7 
pfu. At 2 days after treatment with adenovirus, 
we started to administer either cRGD (200 µg/100 µL saline) or saline intraperitoneally 3 times 
per week. The survival time of mice treated with Ad-REIC and cRGD combined was 
significantly longer than that of those treated with Ad-LacZ or Ad-REIC alone (median survival 
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= 25, 19, and 19 days, respectively; P = 0.0002). 
 
Figure 10  
The mice were sacrificed at 3 weeks after treatment, and the brains treated with Ad-LacZ (2.0 × 
10
7
 pfu) (A), Ad-REIC (2.0 × 10
7
 pfu) (B), and Ad-REIC (2.0 × 10
7
 pfu) and cRGD combined 
(C) were analyzed using the TUNEL assay. An increased number of apoptotic cells (brown) in 
tumors treated with Ad-REIC and cRGD combined compared with Ad-REIC and control was 
observed. (A) Ad-LacZ, 2.2%; (B) Ad-REIC, 13.8%; (C) Ad-REIC and cRGD, 59.3%. Bar = 
100 μm. Mean ± SD. *P = 0.0044, **P < 0.0001. 
 
Supplementary figure 1 
Expression levels of REIC/Dkk-3 protein in U87ΔEGFR glioma cells after treatment with 
Ad-REIC and cRGD. U87ΔEGFR cells were infected with Ad-REIC or Ad-LacZ at an MOI of 
10. At 3 h after infection, the cells were incubated in media containing cRGD at a concentration 
of 0.1 μM. (A) The expression levels of REIC/Dkk-3 protein in U87ΔEGFR glioma cells after 
treatment with Ad-REIC and cRGD were increased as well as in cells treated with Ad-REIC 
alone. (B) Quantification of the expression ratio (average expression levels: Ad-LacZ, 1; 
Ad-LacZ+ cRGD, 1.205; Ad-REIC, 6.157; Ad-REIC+cRGD; 6.240). Protein band density was 
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calculated using ImageJ software. Mean ± SD. * P < 0.001. 
